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OBJECTIVES: The aim of this study is to present a survey of vulnerabilities and to suggest approaches for the
treatment of rare diseases according to the perceptions of a group of affected individuals, patient association
representatives and health care professionals.
METHODS: The focus group technique was used in interviews with patients and primary caregivers, patient
support groups/non-governmental organizations, primary health care professionals and physician specialists.
RESULTS: The transcript analysis focused on thematic units, which were tailored to each group and allowed
comparisons in search of concordant views. Unanimity was observed in relation to the physical, emotional and
social damage to the life standards of the affected individuals and their families as a result of illness. The
Brazilian health system was unanimously classified as inadequate to respond to the needs of patients with rare
diseases, and this inadequacy led to unpleasant experiences, such as the seemingly endless referrals among
health services to reach a final diagnosis and develop a treatment plan.
CONCLUSIONS: The complex set of health system requirements necessary to support the care of patients with
rare diseases represents an obstacle to successfully meeting the needs of patients and their families. Therefore,
it is important to develop specific public policies to create referral services, guarantee access to appropriate
therapeutic modalities and incorporate technologies that promote research for developing new, affordable
therapies.
KEYWORDS: Diagnosis; Therapy; Rare Diseases; Research; Qualitative Study; Vulnerability.
’ INTRODUCTION
According to the World Health Organization, a disease is
considered rare when it affects 1.3 in 2000 persons. There are
approximately 7,000 known rare diseases (RDs), 80% of
which are genetic in origin; the remaining diseases may be
caused by environmental, infectious or immunological
factors (1-4).
RDs are known for their unique, complex characteristics,
which may lead to chronic clinical deterioration and gradual
interference with social, physical and psychological aspects
of the patient’s daily life, with a direct negative impact on the
overall wellbeing of the nuclear family (1,3).
The public health system has been the primary source of
RD diagnosis and treatment. However, the lack of structured
health policies and regional referral centers forces patients and
caregivers to face an endless pilgrimage to successive health
centers in search of a final diagnosis and proper treatment (2).
Considering the need to individualize and prioritize RD
diagnosis and treatment, the present study aimed to evaluate
vulnerabilities and suggest approaches for RD diagnosis and
treatment in Brazil based on the perceptions of those involved
in the process: patients, caregivers, patient support groups,
non-governmental organizations and primary and tertiary
care professionals (5,6).
’ METHOD
This cross-sectional qualitative study used non-random
sampling. The study included 27 participants divided into
four groups: patients and primary caregivers (PC; G1); patient
support groups and non-governmental organizations (G2);
primary care health professionals (G3); and tertiary care
physician specialists (G4), as described in Table 1. After the
study objectives were presented, all the participants signed
an informed consent form.DOI: 10.6061/clinics/2018/e68
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The researchers involved in the study served as modera-
tors and reporters in each group to ensure procedural homo-
geneity. A script containing guidelines was presented to each
group before the session was initiated (7-9).
The reports were recorded and transcribed in full and served
as a basis for the thematic and categorical content analysis
(10,11). The thematic units were coded and processed with
NVivo 10 software, which allowed us to map their distribution
among the different study groups (12,13). For better reliability,
data triangulation was used to achieve the highest degree of
convergence among the researchers’ perceptions.
The procedures adopted in this study followed the ethical
criteria for research on humans, as written in resolution
number 466/2012 of the National Health Council. This study
was approved by the Ethics Committee for Review of
Research Projects (Comitê de Ética para Análise de Projetos
de Pesquisa - CAPPesq) of Hospital das Clínicas of the FMUSP
(process 268.417, May 8, 2013) (14).
’ RESULTS AND DISCUSSION
The group approach promoted a high level of interaction
among the participants, which enhanced the exchange of
ideas regarding the multiple encountered difficulties related
to diagnosis and access to treatment modalities. Intense
discussions and vivid reports were equally present in the
four study groups. The analysis concentrated on thematic
units in terms of the group in which they occurred, which
allowed the detection of the participants’ consonant opinions
regardless of the stratum to which they belonged (Table 2).
As chronic diseases, RDs present an extended course that
negatively affects several functional features and impact
multiple aspects of the patient’s life, including the frequent
impairment of inclusion in social activities. These conse-
quences tend to involve the entire family, particularly the
inner circle of relatives, creating high levels of stress and the
possible disruption of family ties and physical problems, as
described by Goble (2004) and in fragments of the ‘‘speeches’’
recorded in the present study during the interactive group
activity (1,15-19). These fragments are presented below in italic
print.
You lose all your friends, your whole family; your doorbell and
phone do not ring anymore because whenever you call your
relatives, they already think you are going to ask for something,
and when you do, they label you an opportunist. ‘‘You are
willing to take advantage of your child's disease; you are using
the disease to travel and obtain financial advantages.’’ (G1)
My daughter started to show symptoms of lung disease at an
early age. She failed her last year of senior high school because she
constantly felt sick, and because of this, she was accused of being
lazy, but in fact, she was tired from not being able to breathe. (G1)
I lost my job due to prejudice and was reinstated by court
decision. Such is a sick person's life in Brazil: on top of the
burden of disease, we carry a very strong stigma, which deeply
affects us emotionally. (G1)
The possibility of experiencing social stigma on top of
physical and psychological pain was present in the narra-
tives of the patients and their caregivers. Part of this suffering
could be alleviated with a prompt and correct diagnosis,
which would facilitate the development of coping strategies
and the search for supportive treatment.
However, the present study shows that during the search
for a diagnosis, an individual with an RD is exposed to
situations that increase their feelings of fragility and help-
lessness, as described below.
The greatest difficulty is the establishment of an accurate diagnosis.
So frequently, these patients circulate from one health facility to
Table 2 - Distribution of thematic units among the groups.
Thematic units Groups in which the theme emerged
Physical, emotional and social repercussions experienced by patients and caregivers 1 and 3
History of ‘‘pilgrimage’’ 1, 2 and 3
Delays in examination, treatment and medicine 1, 2, 3 and 4
Difficulties encountered by doctors in the diagnosis of patients 1, 2, 3 and 4
Difficulties encountered by doctors in providing treatment 2, 3 and 4
Judicialization as a way to gain access to treatment 1 and 3
Training and qualification of health professionals 1, 2, 3 and 4
Creation of a referral center and a referral and counter-referral system for the
dissemination of information on RDs
1, 2, 3 and 4
Groups 1: Patients and primary caregivers; 2: Primary health care professionals; 3: Non-governmental associations and organizations; 4: Physician
specialists.
Table 1 - Distribution of the participants in the focus groups according to homogeneity criteria.
Group Composition Number of participants Guiding questions Duration
1 Patients and primary caregivers 07  Diagnosis






 Referrals and access to treatment
 Community resources and child and family support
87 min
3 Primary care health professionals 04  Dynamics of caring for patients with RDs
 Primary health care and patient care
58 min
4 Physician specialists 07  Characterization of the activities of doctors
 How to qualify experiences in the care of patients with RDs
65 min
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another until a given disease is suspected or identified and they are
finally referred to appropriate specialists. (G2)
Therefore, the person is already fragile, particularly nowa-
days. It is more understandable for a person of my age, but it is
very difficult for a younger person who stands there like a guinea
pig. ‘‘They’’ brought a jug with hot water, dipped my daughter's
hand in it and then put her hand in a bowl of ice. You can
imagine the pain she felt, as she has a skin disease. She passed out
from the pain. She had to suffer all this in the presence of medical
students for them to identify her disease. From that day on, I have
never taken my daughter back to a university hospital. I saw her
fainting from pain. ‘‘Ah, let's see how that hand looks’’. Everyone
holding a camera; one brings hot water and puts her hand in it,
which starts to become cyanotic, and then puts it on the ice. The
child could not stand it. My pain was even stronger for having
allowed such a procedure. Then, she told me: ‘‘Mom, I don't want
this anymore. Let me die.’’ (G1)
Although current advances in the medical field have
facilitated the diagnosis of various diseases, the scientific and
technological arsenal is ineffective if it is not made available
to health professionals during academic training or through
continued medical education. RD recognition is highly
dependent on the effective transfer of updated scientific
information to health professionals (3,4,16,18-21). This reality
is described below.
Many professionals have never heard of (some types of RD).
Doctors, OB-GYN specialists, nurses, pediatricians, neonatal
medicine specialists... have never seen it, and when they face it,
their clinical interpretation of the clinical findings may lead
them in the wrong direction (G3).
The patient’s journey does not end with the diagnosis of
the disease; another significant obstacle faces health person-
nel and relatives after diagnosis: the challenge of searching
for adequate treatment, which, at least in Brazil, is far from
straightforward. The Brazilian public health system has been
unable to meet the needs of RD patients who, due to the
multiplicity of these diseases and their rarity, are frequently
unable to organize a strong and representative support
group, as described below (1,20).
The challenges are huge, and we realize it. There is a waiting
list to get an appointment with a specialist that sometimes,
depending on the specialty, is longer than one year. Sometimes,
the patient dies before the scheduled clinic appointment because
he was not rated as a priority (G2).
Primary care health professionals and physician specialists
also experience great discomfort regarding RD patients
because the reference and counter-reference system is slow
and ineffective and presents another obstacle on the journey
to treatment, as described below.
There are difficulties in referring the patient to a specialized
center. The information regarding where to refer patients with
specific diseases is not organized. Depending on the disease, the
patient will need additional care provided by non-medical
health professionals, and these may not always be available –
and many times are out of reach. (G3)
The desire to have a network (interconnected health services)
is very strong, but it is not available. There is no organized
management mechanism; the patient and his family go back and
forth with the reference request document for a long time before
they reach the right place. (G2)
From a clinical point of view, it is fundamental that we are
able to conduct a presumptive diagnosis for the patients arriv-
ing in critical condition. Exams based on simple biochemical
methodology are available, but whenever a more accurate
diagnosis is necessary, such as an enzymatic or genetic deter-
mination, these techniques are generally unavailable, and the
final diagnosis is delayed. It is possible to send the biological
samples to another state or to another country, but it may take
one or two months to get the results back, and the child may die
before the results arrive. Another issue is financial; the hospital
cannot always afford to send the biological samples to another
center, and therefore, we may find ourselves very alone, trying to
perform miracles or find a friend who may help us for free in
order to reach a presumptive diagnosis. (G4)
The global financial and economic context has promoted
the adoption of cost-saving measures, which inevitably has
taken a toll on health systems. Therefore, the legal battle for
access to therapies that the health system does not consider
a priority has been the most effective strategy for many
patients once conventional alternatives have been exhausted.
This practice, however, has been widely debated in the
legal environment, where it has triggered considerable
controversy because while public managers aim to allocate
resources to promote universal access to health care, the
judicial system tries to ensure the rights and meet the needs
of patients with RDs, as described by Andrade (2008) (16).
Although judicialization is the fastest and the most reliable
method for legitimizing access to individual therapeutic
assistance, its indiscriminate use deepens the perversity of
the health system because it favors certain groups over
others. However, some of the actions taken could be avoided
with investments in the development of technologies aimed
at differentiated consumers.
Regarding medications for RDs or ‘‘orphan drugs’’, there is
a lack of incentive for the national pharmaceutical industry
to conduct research and testing related to the manufacture
of these medications. Consequently, these drugs must be
imported, which leads to greater public costs (4-6,22-26).
In fact, it (the orphan drug) has not been released by ANVISA
(the National Health Surveillance Agency), but we can obtain it
through existing laws that regulate orphan drugs. In cases in
which there is only one drug for a disease on a worldwide basis,
Brazilian law will then release it provided it is approved in
Europe or in the United States. By law, ANVISA is obligated to
release medicine for import, and we have already obtained some
as a result of this fact. (G3)
Although the Unified Health System [Sistema Único de
Saúde - SUS] has several flaws in its main programs for the
general population, the people interviewed in the present
research presented innumerable suggestions for improve-
ments to meet the needs of minority groups.
The most commonly cited suggestions for optimizing the
medical care provided to RD patients were to increase
investment in the training and qualification of health
professionals and to create a model of care that includes an
efficient communication flow between multi-professional
teams of primary care and referral/specialized professionals
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that are responsible for diagnosis, treatment and providing
psychological support to patients and their families, as
described below.
It is my opinion that a course should be included in the univer-
sity academic curriculum to introduce the RD topic, as there
currently is none. (G1)
Another important aspect is to qualify and train professionals
so they can have an accurate perception (of RDs), to conduct
home visits as early as possible, and to work in conjunction
with the community and community health agents because they
are the connecting point between the community and health
professionals. (G2)
It is necessary to have a multidisciplinary team to take care of
the child (with an RD) starting at her/his birth. Additionally,
it is necessary to have someone to support the desperate family.
That way, the treatment will reach not only the child but also
the family as a whole. (G3)
Reference centers for research, diagnosis, treatment and
the dissemination of information on RDs exist in countries
such as Portugal, Belgium, Italy and the United Kingdom.
In our society, the existence of centers for the most prevalent
diseases and for specific groups provides a glimpse into the
possibility of creating centers for people affected by an RD.
This system has been suggested as an alternative to avoid the
burnout of professionals, caregivers and patients, as descri-
bed below (1,3,4).
Considering that everyone needs a multidisciplinary team, an
institute for this purpose should be created since the prevalence
of different RDs is high. (G1)
Considering that both women's and children's institutes are
already in place, I understand a specific institute for RDs should
be created. (G1)
We (tertiary care centers) function at primary, secondary and
tertiary levels. We receive patients from all over the country
who are erroneously diagnosed and referred for the care of a
certain disease because the primary doctor was not able to
determine a proper clinical diagnosis and sent the patient to
our attention for a solution. This is a waste of time and money,
but it is much easier for the state of origin to pay for the
patient's trip to come to our hospital (Hospital das Clı´nicas in
São Paulo City). (G4)
Even if there is no health system that can serve all who
need it equally, this should not be an excuse for individuals
with responsibilities in these systems. To that effect, recent
national initiatives such as Ordinance 199, which was passed
by the Ministry of Health on January 30, 2014, and the
Brazilian Law of Inclusion, which has been in effect since
July 6, 2015, are attempts to rethink inclusion policies and
to direct attention toward people affected by some type of
RD (27,28).
’ CONCLUSION
The complexity of RDs presents obstacles and severe stress
factors for patients, their families, and health professionals.
To address these obstacles, the present study underscores the
need to reduce the time between RD diagnosis and treatment
initiation.
The most significant challenge in the Brazilian environ-
ment lies in the urgent need to disseminate awareness about
RDs in the academic environment and to create public
policies that ensure access to orphan drugs and rehabilita-
tion, such as those available in many developed countries.
Furthermore, it is common sense that additional needs of RD
patients could be met if appropriate technologies were direc-
ted toward research aimed at developing new, more access-
ible and affordable therapies.
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